Clinical Trial Update: Xeltis Bioabsorbable Pulmonary Valved Conduit Pivotal Study [NA]

View source ↗

Summary

Xeltis reports that its pivotal study of a bioabsorbable pulmonary valved conduit for congenital heart defects is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Heart Defect

Snippet

Sponsor: Xeltis | Conditions: Heart Defect, Congenital | NA | Status: ACTIVE_NOT_RECRUITING